Unveiling Cardinal Health (CAH)''s Value: Is It Really Priced Right? A Comprehensive Guide

Neurocrine Biosciences Inc (NASDAQ: NBIX ) announced positive topline data from the Phase 3 CAHtalyst Adult Study evaluating crinecerfont in adults with classic congenital adrenal hyperplasia (CAH) due to 21-hydroxylase deficiency (21-OHD) . CAH is a group of genetic conditions limiting hormone production in the adrenal glands. These glands produce hormones your body needs to function properly. Also Read:

Summer is unofficially over, but what a difference a year makes. The S&P 500 lost 19% in 2022 yet has rallied 17% higher since the end of July. And if you look at how far the popular index has come from its lows, up 26%, that constitutes a bull market run to many. But it also means it’s time to add some safe stocks to your portfolio. It’s easy to say the good times will continue to roll, and there is some historical precedence to back that up . Bull markets tend to be measured in years, while bear markets typically end in months. But the Federal Reserve is warning there is a 66% chance of recession coming in H2 2023. Borrowers have to begin repaying their student loans this month. That could take a big chunk of discretionary spending out of the hands of consumers. Coupled with the fact that most of the benchmark index’s gains result from the Magnificent seven tech stocks’ strong performance , the landscape might not be as rosy as it appears. That’s why you should consider the following three safe stocks to buy.

Cardinal Health sees its Relative Strength Rating move into the 80-plus level.

Michelle Greene , Chief Information Officer at Cardinal Health (NYSE: CAH ), reported a large insider sell on August 17, according to a new SEC filing. What Happened: A Form 4 filing from the U.S. Securities and Exchange Commission on Thursday showed that Greene sold 2,000 shares of Cardinal Health . The total transaction amounted to $173,580. Cardinal Health shares are trading down 0.14% at $86.27 at the time of this writing on Friday morning. Now trade stocks online commission free with Charles Schwab, a trusted and complete investment firm. Why Insider Transactions Are Important Insider transactions shouldn''t be used primarily to … Full story available on Benzinga.com

Cardinal Health (NYSE:CAH – Get Free Report) had its price objective raised by equities researchers at Morgan Stanley from $92.00 to $100.00 in a research note issued to investors on Wednesday, Marketbeat.com reports. The firm currently has an “overweight” rating on the stock. Morgan Stanley’s target price suggests a potential upside of 15.75% from the […]

Is Cardinal Health (CAH) a Fairly Valued Stock? An In-depth Analysis

Shares of Cardinal Health, Inc. (CAH) are sliding more than 3 percent on Thursday morning trade, continuing a bearish trend since August 14. There have been no corporate announcements today to hurt the stock movement.

Research analysts at StockNews.com began coverage on shares of Cardinal Health (NYSE:CAH – Get Free Report) in a research report issued to clients and investors on Thursday. The brokerage set a “strong-buy” rating on the stock. Several other brokerages have also recently issued reports on CAH. TD Cowen increased their target price on Cardinal Health […]

Cardinal Health Inc (NYSE: CAH ) reported better-than-expected fourth-quarter earnings and raised its guidance. Cardinal Health reported fourth-quarter adjusted EPS of $1.55, up 48% Y/Y, beating the consensus of $1.48. Sales increased 13% to $53.45 billion, beating the consensus of $52.41 billion. Cardinal Health … Full story available on Benzinga.com